Phase 3 data of mdc-IRM first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia
11/15/2021
Phase 3 data of mdc-IRM, first product based on MedinCell’s […]
Latest news
Phase 3 data of mdc-IRM first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia
Fast expanding portfolio
Already 3 programs in Clinical
PRECLINICAL & CLINICAL DEVELOPMENT
As of June, 2021
IMPACT HEALTH
Business model
Building a global pharma leader through long-acting injectables working with NGOs, Private Sector, and Academics
Who we are
Who we are
Our strength is our people
MedinCell is operated by our talented employees who have come together from around the world to achieve our mission of Better Medicine for All.
Through purposeful innovation, we aim to improve the treatments available to patients. And we believe that everyone should have access to best-in-class medication, so we focus on making our products available regardless of local economic conditions. To ensure access, we work on both for-profit and non-profit projects, in collaboration with highly valued partners ranging from big pharmas to physicians, from biotech firms to academics and foundations. Most importantly, our partners share our values based on trust and transparency.
